• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by STERIS plc (Ireland)

    5/30/25 4:31:04 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    SD 1 d55138dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    SPECIALIZED DISCLOSURE REPORT

     

     

    STERIS plc

    (Exact name of registrant as specified in its charter)

     

     

     

    Ireland   001-38848   98-1455064

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    70 Sir John Rogerson’s Quay, Dublin 2, Ireland

    DE21 6LY

    (Address of principal executive offices)

    J. Adam Zangerle

    Registrant’s telephone number, including area code: + 353 1 232 2000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______________.

     

     
     


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure

    This Form SD of STERIS plc is filed pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1 through December 31, 2024.

    We have evaluated our current product lines and determined that certain products we manufacture or contract to manufacture may contain tin, tungsten, tantalum and/or gold.

    The brief description of our reasonable country of origin inquiry (“RCOI”) process, the results of our inquiry, and the determination we reached as a result of our RCOI process are included in our Conflict Minerals Report attached as an exhibit to this Form SD.

    A copy of the Company’s Conflict Minerals Report is filed as Exhibit 1.01 hereto and is publicly available at: https://sterisplc.gcs-web.com/financials/sec-filings. The content of any website referred to in this Form SD is not incorporated by reference in this Form SD.

    Item 1.02 Exhibit

    A copy of the Company’s Conflict Minerals Report as required by Item 1.01 and Item 1.02 is filed as Exhibit 1.01 hereto.

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not Applicable

    Section 3 – Exhibits

    Item 3.01 Exhibits

    The following exhibit is filed as part of this report.

    Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

     

    2


    EXHIBIT INDEX

     

    Exhibit Number

      

    Description of Exhibit

    1.01    Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    STERIS plc    
    By:  

    /s/ Michael J. Tokich

        May 30, 2025
      Michael J. Tokich    
      Senior Vice President and Chief Financial Officer    

     

    4

    Get the next $STE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    4/7/2022$275.00Outperform
    Wolfe Research
    More analyst ratings

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Steris with a new price target

      Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

      5/29/25 8:18:41 AM ET
      $STE
      Industrial Specialties
      Health Care
    • Steris upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

      10/24/24 6:28:31 AM ET
      $STE
      Industrial Specialties
      Health Care
    • KeyBanc Capital Markets resumed coverage on Steris with a new price target

      KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00

      2/6/24 6:38:21 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    SEC Filings

    See more
    • SEC Form SD filed by STERIS plc (Ireland)

      SD - STERIS plc (0001757898) (Filer)

      5/30/25 4:31:04 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by STERIS plc (Ireland)

      10-K - STERIS plc (0001757898) (Filer)

      5/29/25 4:36:38 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by STERIS plc (Ireland)

      144 - STERIS plc (0001757898) (Subject)

      5/20/25 4:10:47 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $STE
    Leadership Updates

    Live Leadership Updates

    See more

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SVP and President, Healthcare Majors Cary L exercised 12,828 units of Ordinary Shares at a strike of $147.05 and sold $3,208,026 worth of Ordinary Shares (12,828 units at $250.08) (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      5/22/25 4:31:17 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SVP and President, Healthcare Majors Cary L sold $365,532 worth of Ordinary Shares (1,682 units at $217.32), decreasing direct ownership by 13% to 11,372 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      11/27/24 4:30:15 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 91 units of Ordinary Shares, decreasing direct ownership by 0.27% to 33,251 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      10/2/24 4:37:12 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/13/24 5:14:05 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:49:03 AM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:32:52 AM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • STERIS Announces Changes to Board of Directors

      David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

      5/11/21 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Financials

    Live finance-specific insights

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care